The "Pharmaceutical Current Good Manufacturing Practices (CGMPs) for the 21st Century--A Risk Based Approach" initiative was ...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene ...

Electric vehicle company Canoo Inc has advanced its U.S. manufacturing timeline to begin production before the fourth quarter next year, and would expand to more locations apart from its Oklahoma ...

Graphjet Technology expects to commission new facility by the end of Q2 2024, with revenues and production expected in 2024 Facility expected to transform 9,000 tonnes of agriculture waste annually to ...

While USAR has been seen as pre-revenue, buried in analyst snapshots is a $38.4 million revenue estimate for FY2025, suggesting commercial production or contracted offtake is closer than assumed.

The global viral vector manufacturing market is projected to expand at a robust CAGR of approximately 20% over the forecast period, supported by multiple transformative forces reshaping the ...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene ...